Brain, Vol. 124, No. 2, 437-443,
February 2001
© 2001 Oxford University Press
Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus–myoclonus
.
1 Service of Neurology. Hospital Universitari La Fe, Valencia and 2 Service of Neurology and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain
Correspondence to:
Francesc Graus, MD, Servei de Neurologia, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain. E-mail: graus{at}medicina.ub.es
We analysed a series of 24 adult patients with idiopathic (10 cases) and paraneoplastic (14 cases) opsoclonus–myoclonus syndrome (OMS) to ascertain possible differences in clinical course and response to immunotherapies between both groups. Associated tumours were small-cell lung cancer (SCLC) (nine patients), non-SCLC (one patient), breast carcinoma (two patients), gastric adenocarcinoma (one patient) and kidney carcinoma (one patient). Patients with paraneoplastic OMS were older [median age: 66 years versus 40 years (P = 0.006) of those with idiopathic OMS] and had a higher frequency of encephalopathy (64% versus 10%; P = 0.02). Serum from 10/10 idiopathic and 12/14 paraneoplastic OMS patients showed no specific immunoreactivity on rat or human brainstem or cerebellum, lacked specific antineuronal antibodies (Hu, Yo, Ri, Tr, glutamic acid decarboxylase, amphiphysin or CV2) and did not contain antibodies to voltage-gated calcium channels. The two paraneoplastic exceptions were a patient with SCLC, whose serum contained both anti-Hu and anti-amphiphysin antibodies and a patient with breast cancer who had serum anti-Ri antibodies. The clinical course of idiopathic OMS was monophasic except in two elderly women who had relapses of the opsoclonus and mild residual ataxia. Most idiopathic OMS patients made a good recovery, but residual gait ataxia tended to persist in older patients. Immunotherapy (mainly intravenous immunoglobulins or corticosteroids) seemed to accelerate recovery. Paraneoplastic OMS had a more severe clinical course, despite treatment with intravenous immunoglobulins or costicosteroids, and was the cause of death in five patients whose tumours were not treated. By contrast the eight patients whose tumours were treated showed a complete or partial neurological recovery. We conclude that idiopathic OMS occurs in younger patients, the clinical evolution is more benign and the effect of immunotherapy appears more effective than in paraneoplastic OMS. In patients aged 50 years and older with OMS who develop encephalopathy, early diagnosis and treatment of a probable underlying tumour, usually SCLC, is indicated to increase the chances of neurological recovery. At present, there are no immunological markers to identify the adult patients with paraneoplastic OMS.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. R. Patel, R. M. Subramaniam, J. N. Mandrekar, J. E. Hammack, V. J. Lowe, and J. R. Jett Occult Malignancy in Patients With Suspected Paraneoplastic Neurologic Syndromes: Value of Positron Emission Tomography in Diagnosis Mayo Clin. Proc., August 1, 2008; 83(8): 917 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Fitzpatrick, O. M. Gray, J. McConville, and G. V. McDonnell OPSOCLONUS-MYOCLONUS SYNDROME ASSOCIATED WITH BENIGN OVARIAN TERATOMA Neurology, April 8, 2008; 70(15): 1292 - 1293. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ramat, R. J. Leigh, D. S. Zee, and L. M. Optican What clinical disorders tell us about the neural control of saccadic eye movements Brain, January 1, 2007; 130(1): 10 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Peter, J Jung, C Tilikete, P Ryvlin, and F Mauguiere Opsoclonus-myoclonus as a manifestation of Lyme disease. J. Neurol. Neurosurg. Psychiatry, September 1, 2006; 77(9): 1090 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P M Candler, R C Dale, S Griffin, A J Church, R Wait, M D Chapman, G Keir, G Giovannoni, and J H Rees Post-streptococcal opsoclonus-myoclonus syndrome associated with anti-neuroleukin antibodies J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 507 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Llado, P. Mannucci, A. F. Carpentier, S. Paris, Y. Blanco, A. Saiz, J. Y. Delattre, and F. Graus Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes Neurology, November 23, 2004; 63(10): 1947 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vernino, B. P. O'Neill, R. S. Marks, J. R. O'Fallon, and D. W. Kimmel Immunomodulatory treatment trial for paraneoplastic neurological disorders Neuro-oncol, January 1, 2004; 6(1): 55 - 62. [Abstract] [PDF]
|
|
|
|
|
|
F Blaes, M Jauss, J Kraus, P Oschmann, I Krasenbrink, M Kaps, and B Teegen Adult paraneoplastic opsoclonus-myoclonus syndrome associated with antimitochondrial autoantibodies J. Neurol. Neurosurg. Psychiatry, November 1, 2003; 74(11): 1595 - 1596. [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Darnell and J. B. Posner Paraneoplastic Syndromes Involving the Nervous System N. Engl. J. Med., October 16, 2003; 349(16): 1543 - 1554. [Full Text] [PDF]
|
|
|
|
|
|
K Glatz, H-M Meinck, and B Wildemann Parainfectious opsoclonus-myoclonus syndrome: high dose intravenous immunoglobulins are effective J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 279 - 280. [Full Text]
|
|
|
|
|
|
A Serra and R J Leigh Diagnostic value of nystagmus: spontaneous and induced ocular oscillations J. Neurol. Neurosurg. Psychiatry, December 1, 2002; 73(6): 615 - 618. [Abstract] [Full Text] [PDF]
|
|